Terns Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Amy Burroughs

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

Terns Pharmaceuticals: Another Potential GLP-1 Entrant

Oct 21

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Sep 25

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Sep 10

We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Aug 18

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

May 03

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Jan 12

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Sep 29

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Jun 06

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Feb 21

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Oct 03

Terns Pharmaceuticals: The Easy Money Has Been Made

Sep 20

Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08

Aug 08

Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Jun 14

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Mar 16

We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

Nov 24

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Aug 24

Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study

Jun 14

CEO

Amy Burroughs (54 yo)

less than a year

Tenure

Ms. Amy L. Burroughs, M.B.A., serves as CEO & Director at Terns Pharmaceuticals, Inc. from February 07, 2024. She serves as Independent Director of Tenaya Therapeutics, Inc. since December 2022. She had be...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Vignola	CFO & Treasurer	4.3yrs	US$3.14m	0.027% $ 167.9k
Amy Burroughs	CEO & Director	less than a year	geen gegevens	geen gegevens
Elona Kogan	Chief Legal Officer	less than a year	geen gegevens	geen gegevens
Jeffrey Jasper	Senior Vice President of Research	2.8yrs	geen gegevens	geen gegevens
Emil Kuriakose	Chief Medical Officer	1.5yrs	geen gegevens	geen gegevens
Melita Jung	Chief Business Officer	less than a year	geen gegevens	geen gegevens
Scott Harris	Chief Development Officer	less than a year	geen gegevens	geen gegevens
Debra Sieminski	Senior Vice President of Medical Affairs	less than a year	geen gegevens	geen gegevens
David Strauss	VP of Finance & Controller	less than a year	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

46.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TERN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Amy Burroughs	CEO & Director	less than a year	geen gegevens	geen gegevens
Carl Gordon	Independent Director	6.1yrs	US$298.99k	0% $ 0
Jeffrey Kindler	Independent Director	3.9yrs	US$304.99k	0% $ 0
Hongbo Lu	Independent Director	4.6yrs	US$299.99k	0.56% $ 3.4m
Joe Shih	Member of Scientific Advisor	no data	geen gegevens	geen gegevens
David Fellows	Independent Chairman	3.9yrs	US$340.15k	0% $ 0
Stephen A. Harrison	Member of Scientific Advisor	no data	geen gegevens	geen gegevens
Juan Lopez-Telavera	Member of Scientific Advisor	no data	geen gegevens	geen gegevens
Radhika Tripuraneni	Independent Director	2.3yrs	US$303.06k	0% $ 0
Michael Charlton	Member of Scientific Advisor	no data	geen gegevens	geen gegevens
Jill Quigley	Independent Director	3.9yrs	US$480.49k	0.018% $ 108.6k
Ann Taylor	Independent Director	3.2yrs	US$302.49k	0% $ 0

3.9yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TERN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Terns Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Independent Director recently bought US$5.0m worth of stock

Independent Director exercised options and sold US$141k worth of stock

Terns Pharmaceuticals, Inc. Announces Transition of Mark Vignola as Chief Financial Officer, Effective Until the End of January 2025

Terns Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2024

Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer

Terns Pharmaceuticals, Inc. Announces Leadership Transition

Recent updates

Terns Pharmaceuticals: Another Potential GLP-1 Entrant

Price target increased by 9.5% to US$18.07

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Independent Director recently bought US$5.0m worth of stock

Independent Director exercised options and sold US$141k worth of stock

Terns Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150.149762 million.

Terns Pharmaceuticals, Inc. Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Price target increased by 16% to US$16.50

Terns Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Terns Pharmaceuticals, Inc. Announces Transition of Mark Vignola as Chief Financial Officer, Effective Until the End of January 2025

Terns Pharmaceuticals, Inc. Presents New Preclinical Data Supporting TERN-501 in Combination with A GLP-1R Agonist for Obesity

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

Terns Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2024

Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer

New major risk - Revenue and earnings growth

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 8.9% to US$13.93

Price target decreased by 7.4% to US$14.29

New minor risk - Share price stability

Terns Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

New major risk - Revenue and earnings growth

Terns Pharmaceuticals, Inc. Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-ß Agonist TERN-501 in NASH

Terns Pharmaceuticals, Inc. Announces Leadership Transition

Terns Pharmaceuticals, Inc. Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Price target increased by 8.8% to US$16.14

Price target increased by 7.5% to US$14.83

Price target increased by 9.5% to US$13.80

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Price target increased by 33% to US$11.50

Price target increased to US$8.67

Price target increased to US$6.67

High number of new and inexperienced directors

Terns Pharmaceuticals, Inc. Highlights Results from Phase 1 Clinical Trial of Tern-501 At AASLD The Liver Meeting® 2022

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Price target increased to US$6.67

Terns Pharmaceuticals: The Easy Money Has Been Made

Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08

Terns Pharmaceuticals, Inc. Announces Appointment of Radhika Tripuraneni to Board of Directors

Terns Pharmaceuticals, Inc.(NasdaqGS:TERN) dropped from Russell 2500 Value Index

Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress 2022

Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer

No longer forecast to breakeven

Terns Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

High number of new and inexperienced directors

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Forecast to breakeven in 2024

We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

Co-Founder & Executive Officer notifies of intention to sell stock

Terns Pharmaceuticals, Inc. Completes Part 1 Enrollment of Aviation Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

Terns Pharmaceuticals, Inc. Reports Positive Top-Line Results from Phase 2a Lift Study of FXR Agonist TERN-101 in Patients with NASH

Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study

Terns Pharmaceuticals, Inc. has completed an IPO in the amount of $127.5 million.

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd